Chemotherapy (CT) has brought about a considerable improvement in the survival of patients with advanced Hodgkin's disease (HD). The combination CT regimens of mustine, vincristine or vinblastine, procarbazine and prednisolone (MOPP or MVPP) have been shown to produce complete remissions (CR) in 71-77% of patients with 57-66% of stage IIIB/IV patients remaining alive five years from diagnosis (Sutcliffe et al., 1978; DeVita et al., 1980; Bakemeier et al., 1984; Bonadonna et al., 1986; Wagstaff et al., 1986) . More intensive CT regimens may improve these results with CR rates of 81-89% and five year survival rates of 80-82% have recently been reported (Bonadonna et al., 1986; Young et al., 1982; Klimo et al., 1985) . However, treatment related morbidity and mortality are considerable. Actuarial estimates of the percentage of patients likely to develop second cancers with such treatment are of the order of 10% at 10 years, many of these being fatal Glick et al., 1982; Tester et al.,1984; Dorreen et al., 1986) and the majority of male patients are likely to be permanently sterile (Cunningham et al., 1982) .
Identification of pre-treatment characteristics predictive of survival has been attempted in many diseases. One possible use of such information would be to try and tailor treatment to individual patients. This approach is important in Hodgkin's disease, with its relatively high cure rates, where the intensity of CT and radiotherapy (RT), can be altered to increase the chances of cure, or to minimise the treatment related morbidity and mortality. Initial attempts to identify such factors were encouraging (Wagstaff et al., 1986) . A joint study between two different centres, in Manchester (Christie Hospital) and London (St. Bartholomew's Hospital) employing the same basic treatment regimen, was thus initiated to confirm and expand these initial observations.
Patients and methods
Three hundred and one patients, 150 from St. Bartholomew's Hospital (SBH) and 151 from the Christie Hospital, with clinical or pathological stage IIIB or IV disease, are included in the analysis. Pathology was reviewed at each centre. Other entry criteria have been previously described (Sutcliffe et al., 1978; Wagstaff et al., 1986) , MVPP was the treatment of choice at SBH, however, during the period reported, 23/173 patients received ChlVPP or MVPP modifications when age or toxicity was felt to preclude administration of unmodified MVPP. At SBH, the intended number of cycles for patients achieving complete remission (CR) was 6, although a small number of patients received maintenance therapy for up to 4 years. At the Christie Hospital, it was intended that patients should receive 6 cycles after apparent clinical remission. A median of 7 cycles was given. Both groups gave MVPP according to the dose and schedule described by Nicholson et al., 1976 . In both centres RT was given if considered appropriate to sites of previous bulky disease (any area measuring >5 cm or mediastinal width greater than 1/3 transverse chest diameter at T5/6). CR was defined as the complete disappearance of all evidence of disease and the return to normal of all investigations which had been abnormal as a consequence of HD before beginning CT.
Survival was measured from the date of start of CT to the date of death. Survival curves were based on the method of Kaplan and Meier (1978) , statistical significance being determined by the log rank test (Peto et al., 1977) . For the survival curves presented, patients were not censored for deaths from causes other than HD. However analysis was performed both with and without such censoring, and both sets of results are presented in Table II. The significance of the factors listed in Table I in determining the duration of survival was evaluated using a stepwise linear regression method based on Cox's proportional hazards model (Cox, 1972) . The proportionality of the hazards within each subdivision of these factors was tested by stratifying for each factor in turn, and ensuring that the remaining factors were unchanged in effect compared with the overall model (Anderson, 1982 (67) 109 (72) 27 (18) 15 (10) 100 (66) 51 (34) 38 (25) 24 (16) 89 (59) 79 (52) 69 (46) 52 (34) 48 (32) 46 (30) 5 (3) 14 (9) 47 (31) 78 (52) 12 (8) 0 (0) 120 (79) 17 (11) 14 (9) 42 (28) 107 (71) (65) 109 (73) 26 (17) 15 (10) 113 (75) 37 (25) 62 (41) 20 (13) 68 (45) (7) 90 (60) 32 (21) 11 (7) 6 (5) 125 (83) 25 (17) 0 (0) 22 (15) 113 (75) 15 ( (28) 38 (25) 38 (25) 102 (68) 10 (7) 66 (44) 74 (49) 10 (7) Table II ).
Using these tactors, survival curves were drawn for various possible prognostic subgroups and three primary prog-8 nostic categories were identified (see Figure 2 (Figure 4 ). The SBH model appears to fit the Christie data well ( Figure 5 ). No additional statistical significance was gained by further subdividing the SBH data by age above and below 60, although the curves for these two groups were similar to those from the Christie Hospital. Analysis of the combined data identified ' a(t lusmnnhnout. Figure 6 ).
When survival times were censored for deaths from causes other than HD, the significance of all factors remained very similar, with the exception of age (Table II) (Rodgers et al., 1981) . However, this latter . n = 104 analysis included response as a factor. The two centres (DeVita et al., 1980; Carde et al., 1983 ) who examined pleural involvement found it significant, as did the two centres (Peterson, 1982; Pillai et al., 1985) examining the number of sites of extra-nodal disease. Only DeVita et al. (1980) found histological subtype to be important, patients E. = 47 with nodular sclerosing pathology having a significantly shorter survival than the rest. However, a recent review of these data (Kant et al., 1986; Longo et al., 1986) showed histology to no longer be of independent prognostic significance. Schilling et al. (1982) found serum LDH to be (Wagstaff et al., 1986) . No other nts with stages IIIB and IV studies have submitted this factor for multivariate analyses. Christie divided by prognostic Turning to the studies employing univariate analyses, rsis of the SBH data. Young et al., 1983 , found lymphocytopenia (lymphocyte <45yrs or histology nodular count <1 x 1091 -1) at presentation to be a significant nphocyte predominant. 45yrs or histology lymphocyte adverse predictor of survival, though Bjorkholm et al. (1982) did not. Neither performance status (Bakemeier et a., 1984; Jones et al., 1982) nor stage (DeVita et al., 1980; Bakemeier et al., 1984) have been of consistent significance in univariate analysis. In most reports sex has not been an independent prognostic factor, although Longo et al. (1986) found that it contributed to the prediction of tumour related mortality when considered in combination with clinical liver involvement and pleural involvement. This factor was however significant previously (Wagstaff et al., 1986) This agreement in results reported in this analysis was not reached immediately. This was due to a number of problems encountered in the multivariate analysis itself, and merits further discussion. Although much effort has been devoted to certain aspects of validation of the Cox multivariate model approach (Anderson, 1986; Elashoff, 1983; Kay, 1983) , other areas have been largely ignored. No criteria have been established on how to treat individual variables before inclusion in the model, making results difficult to compare. For example, when a continuous variable such as age is being analysed, should it be considered as having a continuous effect on survival, or should it be divided into subgroups, and if so, by what method? The approach taken in this study has been to examine survival curves for the continuous variables at several different cut-off points, in order to allow understanding of the nature of the relationship before inclusion in the model. The relationship between lymphocytopenia and prognosis was initially unclear, and others had used different divisions in their analyses (Young et al., 1983) . However, once a division above and below 0.75 x 1091 -I was used, the results of the two centres were in agreement. This division point showed the maximum effect on survival, and delineated a relatively small bad prognosis group of patients. The differences in significance for this factor between the two centres appeared to be due to differences in the proportions of patients with low counts, not to differences in survival between patients with low as compared to normal counts. Other problems with multivariate analysis include differences in patient populations (for instance histological difference in this analysis) and differences in the factors actually included for analysis.
When significant factors have been defined using multivariate analysis, further confusion may become apparent in defining the different associated prognostic categories and scoring systems. Common sense is required, since direct application of the model can be misleading. The 'additivity' of the factors, i.e. the assumption, implicit in the Cox model, that the effect on survival of each of the factors is additive is often seen to be invalid. One implication of this assumption is that two bad prognostic factors are always considerably worse than one. This is not always true, since a patient's prognosis qan be determined by just one bad factor. Equally, as can be seen in this study, once a patient is in the 'good' prognosis group, having other 'good' prognostic factors will not necessarily further increase his chances of survival.
All these difficulties make it easy to see why different results are produced by different centres, but happily this makes it particularly encouraging that agreement was found between the two sets of data examined in this study. If the patient populations, prognostic factors analysed, and groupings used in the analysis are all defined, it may, in the future, be possible to show reproducibility between centres.
It is encouraging for the treatment of advanced HD that two simple factors can be used to identify patients who are likely to have prolonged survival. These patients form some 55% of the total population, and treatment is likely to be very effective for this group, with a 10 year survival of 77%. The remaining bad risk patients, especially those males with stage IV disease, have a much greater mortality. For this latter group, it may be necessary to use other alternative forms of treatment.
This analysis does not include an analysis of factors predicting for complete response or relapse free survival for reasons of space, but factors affecting CR rate and duration of remission have previously been published for the Christie Hospital patients (Wagstaff et al., 1986) .
